Immunity: The new method predicts body fluid immunity in COVID19 patients.

9, 2020 /--- According to a recent article published in the journal Immunity, Dr. Galit Alter and Professor Helen Chu from Harvard University identified five immunoreactive markers that correctly classify COVID-19 patients and other patients during recovery.
Chu's team registered, collected, and managed the clinical work of the study, collecting samples from hospitalized COVID-19 patients.
the study used samples from 22 people, 12 of whom recovered and 10 died.
. Alter's team used systemic serological techniques to create detailed immune response profiles using more than 60 assays to compare the immune responses of survivors and non-survivors.
SARS-CoV-2, which causes COVID-19, has two main proteins that respond to the body fluid immune system responsible for producing antibodies.
they are the puncture (S) protein and the nuclear shell (N) protein.
(Photo source: www.pixabay.com) "Most of the vaccine candidates being developed are designed to trigger antibodies against the tingling protein, which is the response of individuals who have observed surviving natural infections.
" N protein is significantly higher in viruses than S proteins, but previous studies have shown that immune responses to N proteins do not provide protection against SARS-CoV-2-related coronaviruses.
using systemic serological techniques to learn more about the body fluid immune response, Dr Alter's lab compared the immune responses of the recovering and deceased.
they found that most of the body fluid immune responses in recovering patients responded to the S protein, while the immune capacity of the deceased changed, so they responded more strongly to the N protein.
: "Changes in immune advantages are only apparent when a strong and detailed immune response from different groups of patients is compared," said Alter, a researcher at the U.S. Government.
authors found that this immune benefit shift could be detected by measuring five immune response markers: including the IgM and IgA1 responses to S proteins, and antibody-dependent complement deposition of N proteins, IgM and IgA2 reactions.
using these five markers, the researchers were able to build a model that correctly classified clinical samples as rehabilitation sub-groups and non-rehabused sub-groups.
to validate the model, the authors analyzed 40 clinical COVID-19 samples from Boston, 20 from rehab and 20 from deceased patients.
results showed that the S protein of the deceased shifted to the immune advantage of the N protein in the same way as in patients recovering.
addition, in the samples analyzed, this shift in immune advantage was more accurate in predicting recovery or death than using demographic factors.
The discovery of these early antibody characteristics may have an impact on the evaluation of candidate COVID-19 vaccines to ensure that they produce an immune response similar to that of naturally infected people," Said Chu said.
(bioon.com) Source: Potentialy Information Humoral immune Response Markers in COVID-19 Patients Source: Caroline Atyeo et al, Distinct Early Serological Signatures Track WITH-CoV-2 Survival, Immunity (2020). DOI: 10.1016/j.immuni.2020.07.020.